vs
Bank7 Corp.（BSVN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Bank7 Corp.的1.3倍（$30.3M vs $24.1M），Bank7 Corp.净利率更高（44.7% vs -221.3%，领先266.1%），REGENXBIO Inc.同比增速更快（43.0% vs -0.1%），Bank7 Corp.自由现金流更多（$41.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 0.2%）
Bank7 Corp是美国的金融控股公司，旗下运营全服务社区银行Bank7，提供商业及个人银行产品，包括存款账户、小微企业贷款、商业地产融资及个人贷款解决方案，核心服务区域覆盖俄克拉荷马州、得克萨斯州、堪萨斯州，客群以中小企业和零售客户为主。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BSVN vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$24.1M
营收增速更快
RGNX
高出43.1%
-0.1%
净利率更高
BSVN
高出266.1%
-221.3%
自由现金流更多
BSVN
多$94.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.1M | $30.3M |
| 净利润 | $10.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 58.7% | -190.0% |
| 净利率 | 44.7% | -221.3% |
| 营收同比 | -0.1% | 43.0% |
| 净利润同比 | -2.9% | -31.2% |
| 每股收益（稀释后） | $1.13 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSVNRGNX
| Q4 25 | $24.1M | $30.3M | ||
| Q3 25 | $25.2M | $29.7M | ||
| Q2 25 | $24.4M | $21.4M | ||
| Q1 25 | $22.6M | $89.0M | ||
| Q4 24 | $24.1M | $21.2M | ||
| Q3 24 | $24.9M | $24.2M | ||
| Q2 24 | $24.4M | $22.3M | ||
| Q1 24 | $24.0M | $15.6M |
净利润BSVNRGNX
| Q4 25 | $10.8M | $-67.1M | ||
| Q3 25 | $10.8M | $-61.9M | ||
| Q2 25 | $11.1M | $-70.9M | ||
| Q1 25 | $10.3M | $6.1M | ||
| Q4 24 | $11.1M | $-51.2M | ||
| Q3 24 | $11.8M | $-59.6M | ||
| Q2 24 | $11.5M | $-53.0M | ||
| Q1 24 | $11.3M | $-63.3M |
毛利率BSVNRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BSVNRGNX
| Q4 25 | 58.7% | -190.0% | ||
| Q3 25 | 56.2% | -176.3% | ||
| Q2 25 | 60.2% | -296.3% | ||
| Q1 25 | 60.7% | 13.6% | ||
| Q4 24 | 61.0% | -242.1% | ||
| Q3 24 | 62.2% | -256.6% | ||
| Q2 24 | 62.5% | -251.3% | ||
| Q1 24 | 62.0% | -408.8% |
净利率BSVNRGNX
| Q4 25 | 44.7% | -221.3% | ||
| Q3 25 | 43.0% | -208.3% | ||
| Q2 25 | 45.4% | -331.8% | ||
| Q1 25 | 45.7% | 6.8% | ||
| Q4 24 | 46.0% | -241.3% | ||
| Q3 24 | 47.3% | -246.3% | ||
| Q2 24 | 47.2% | -237.7% | ||
| Q1 24 | 47.0% | -405.4% |
每股收益（稀释后）BSVNRGNX
| Q4 25 | $1.13 | $-1.30 | ||
| Q3 25 | $1.13 | $-1.20 | ||
| Q2 25 | $1.16 | $-1.38 | ||
| Q1 25 | $1.08 | $0.12 | ||
| Q4 24 | $1.16 | $-0.99 | ||
| Q3 24 | $1.24 | $-1.17 | ||
| Q2 24 | $1.23 | $-1.05 | ||
| Q1 24 | $1.21 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $251.0M | $102.7M |
| 总资产 | $2.0B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BSVNRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益BSVNRGNX
| Q4 25 | $251.0M | $102.7M | ||
| Q3 25 | $241.7M | $161.5M | ||
| Q2 25 | $231.9M | $213.7M | ||
| Q1 25 | $221.7M | $274.2M | ||
| Q4 24 | $213.2M | $259.7M | ||
| Q3 24 | $204.2M | $301.4M | ||
| Q2 24 | $190.8M | $348.3M | ||
| Q1 24 | $180.4M | $390.7M |
总资产BSVNRGNX
| Q4 25 | $2.0B | $453.0M | ||
| Q3 25 | $1.9B | $525.2M | ||
| Q2 25 | $1.8B | $581.0M | ||
| Q1 25 | $1.8B | $490.9M | ||
| Q4 24 | $1.7B | $466.0M | ||
| Q3 24 | $1.7B | $519.1M | ||
| Q2 24 | $1.7B | $569.4M | ||
| Q1 24 | $1.8B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $41.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 171.7% | -174.0% |
| 资本支出强度资本支出/营收 | 19.7% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.28× | — |
| 过去12个月自由现金流最近4个季度 | $74.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BSVNRGNX
| Q4 25 | $46.1M | $-52.3M | ||
| Q3 25 | $16.6M | $-56.0M | ||
| Q2 25 | $9.4M | $-49.3M | ||
| Q1 25 | $11.0M | $33.6M | ||
| Q4 24 | $55.0M | $-31.6M | ||
| Q3 24 | $13.4M | $-40.5M | ||
| Q2 24 | $8.1M | $-45.5M | ||
| Q1 24 | $20.4M | $-55.5M |
自由现金流BSVNRGNX
| Q4 25 | $41.4M | $-52.8M | ||
| Q3 25 | $16.4M | $-56.5M | ||
| Q2 25 | $8.8M | $-49.7M | ||
| Q1 25 | $8.2M | $32.6M | ||
| Q4 24 | $50.8M | $-32.7M | ||
| Q3 24 | $12.7M | $-40.9M | ||
| Q2 24 | $6.5M | $-46.0M | ||
| Q1 24 | $19.8M | $-56.0M |
自由现金流率BSVNRGNX
| Q4 25 | 171.7% | -174.0% | ||
| Q3 25 | 65.0% | -189.9% | ||
| Q2 25 | 36.1% | -232.8% | ||
| Q1 25 | 36.3% | 36.6% | ||
| Q4 24 | 210.6% | -154.2% | ||
| Q3 24 | 51.2% | -168.9% | ||
| Q2 24 | 26.8% | -206.2% | ||
| Q1 24 | 82.3% | -358.5% |
资本支出强度BSVNRGNX
| Q4 25 | 19.7% | 1.7% | ||
| Q3 25 | 0.8% | 1.7% | ||
| Q2 25 | 2.6% | 1.8% | ||
| Q1 25 | 12.4% | 1.2% | ||
| Q4 24 | 17.4% | 5.1% | ||
| Q3 24 | 2.5% | 1.3% | ||
| Q2 24 | 6.6% | 2.1% | ||
| Q1 24 | 2.8% | 3.6% |
现金转化率BSVNRGNX
| Q4 25 | 4.28× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 0.85× | — | ||
| Q1 25 | 1.06× | 5.53× | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 1.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSVN
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
